About us Contacts Drug interactions: 390 212
Drug search by name

Targretin and Zovia 1/35e

Determining the interaction of Targretin and Zovia 1/35e and the possibility of their joint administration.

Check result:
Targretin <> Zovia 1/35e
Relevance: 10.11.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Bexarotene may decrease the effectiveness of ethinyl estradiol. If you are using low-dose contraceptives, there is an increased risk of unintended pregnancy during combined therapy with bexarotene. Bexarotene is likely associated with major birth defects, it is particularly important that you do not become pregnant during treatment. Therefore, hormonal contraceptives should not be used as the sole method of birth control in women of childbearing potential treated with bexarotene. Alternative or additional methods of birth control should be used while taking bexarotene. If you take hormone replacement for menopause, notify your doctor if you have decreased efficacy of your hormones. You may notice symptoms of increased hot flashes, vaginal dryness or menstrual abnormalities. It is important that you tell your healthcare provider about all other medications that you are using including vitamins and herbs. Do not stop using your medications without first talking to your doctor first.

Professional:

ADDITIONAL CONTRACEPTION RECOMMENDED: There are no data concerning the potential effect of bexarotene on hormonal contraceptives. Presumably, coadministration with bexarotene may decrease the efficacy of contraceptives containing low-dose estrogens and progestins due to its induction of CYP450 3A4, the isoenzyme that is primarily responsible for the metabolic clearance of sex hormones.

MANAGEMENT: Women using low-dose hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with bexarotene. Because use of bexarotene is likely associated with major birth defects, it is particularly important that patients not become pregnant during treatment. Therefore, hormonal contraceptives should not be used as the sole method of birth control in women of childbearing potential treated with bexarotene. Product labeling recommends that two reliable forms of contraception, one non-hormonal, be used simultaneously during bexarotene therapy and for at least one month following discontinuation of therapy. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed. Intrauterine systems are unlikely to be significantly affected because of their local action.

References
  • Faculty of Sexual & Reproductive Healthcare "FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf." ([2012, Jan 1]):
  • "Product Information. Targretin (bexarotene)" Ligand Pharmaceuticals, San Diego, CA.
Targretin

Generic Name: bexarotene

Brand name: Targretin

Synonyms: n.a.

Zovia 1/35e

Generic Name: ethinyl estradiol / ethynodiol

Brand name: Kelnor, Zovia 1/35, Zovia 1/50, Demulen 1/35, Demulen 1/50, Zovia 1/35e, Kelnor 1/50, Kelnor 1/35, Zovia 1/50e

Synonyms: Zovia 1/35, Zovia 1/35E

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction